3 results
Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…
Augmented Reality cues to reduce Freezing of Gait during turning in persons with Parkinson*s disease
The primary objective of this study is to investigate the effect of visual turning-cues presented in augmented reality on the severity of freezing of gait evoked during turning in patients with Parkinson*s disease. This effect is compared to that of…
Phase I partPrimary:* Determine the maximum tolerated dose (MTD) or the recommended phase II dose (RP2D).Secondary:* Safety and tolerability, * ORR, duration of response (DOR), disease control rate (DCR), progression free survival (PFS) and time to…